Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on April 14, 2025
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness
GlobeNewswire
·
April 14, 2025
Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and …
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
GlobeNewswire
·
April 14, 2025
FLORHAM PARK, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, welcomes action by the Centers for Medicare …
NKGen Biotech To Present on the Use of Troculeucel for Alzheimer’s and Parkinson’s Disease at the 7th China International Biotechnology Conference & Exhibition
GlobeNewswire
·
April 14, 2025
SANTA ANA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer …
HealthLynked Welcomes Anthony Scuilla as Sales Consultant to Drive Strategic Partnerships with Insurance Providers
GlobeNewswire
·
April 14, 2025
NAPLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK), a leader in healthcare technology innovation, is proud to announce the appointment of Anthony "Tony" Scuilla as a strategic sales consultant. In his new role, Mr. …
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
GlobeNewswire
·
April 14, 2025
BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial …
Elutia Confirms No Material Impact from Global Tariffs
GlobeNewswire
·
April 14, 2025
SILVER SPRING, Md., April 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today confirmed that the ongoing global tariff environment has had no material impact on its …
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
GlobeNewswire
·
April 14, 2025
– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process – RMAT review by FDA included initial clinical safety and activity data from ongoing …
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
GlobeNewswire
·
April 14, 2025
– $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts – – Coherus to focus exclusively on its innovative novel oncology programs including: – LOQTORZI®, a revenue- …
Lachine Hospital Foundation Gala raises $406,500 to support the modernization of Lachine Hospital
GlobeNewswire
·
April 14, 2025
The Lachine Hospital Foundation’s signature Gala raised an incredible $406,500 to support the Dream Big: Lachine Hospital campaign, a successful collaboration between the Lachine Hospital Foundation and the MUHC Foundation. The $5 million campaign, is …
Le Gala de la Fondation de l'Hôpital de Lachine amasse 406 500 $ pour soutenir la modernisation de l'Hôpital de Lachine
GlobeNewswire
·
April 14, 2025
Le Gala signature de la Fondation de l'Hôpital de Lachine a permis de recueillir un montant impressionnant de 406 500 $ pour soutenir la campagne Oser Rêver : Hôpital de Lachine, une collaboration réussie entre la Fondation de l'Hôpital de Lachine et la …
Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization
GlobeNewswire
·
April 14, 2025
Reiterates Full-Year 2025 Guidance Arsenal Capital Partners agrees to a one-year lock-up RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced expected revenue and …
Catheter Precision, Inc. Receives Notice of First Patent Allowance in the US for LockeT Product Line
GlobeNewswire
·
April 14, 2025
Fort Mill, S.C., April 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that it has …
SBC Medical Group Holdings, Inc. Purchases 5 BTC
GlobeNewswire
·
April 14, 2025
IRVINE,Calif., April 14, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings (Headquarters: California, USA; CEO: Yoshiyuki Aikawa) hereby announces that, based on the announcement of a decision to purchase Bitcoin (BTC) disclosed on February 12, 2025, it …
Relmada Therapeutics To Present NDV-01 Data at AUA2025
GlobeNewswire
·
April 14, 2025
CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025 …
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
GlobeNewswire
·
April 14, 2025
XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights …
Avicanna Reports Full Year 2024 Audited Financial Statement
GlobeNewswire
·
April 14, 2025
2024 Revenue of $25.5M, a 52% increase from 2023 Consolidated Gross Margins of 51%, Gross Profits of $12.9M, a 94% increase from 2023 TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: …
SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)
GlobeNewswire
·
April 14, 2025
DUBLIN, Ireland and OXFORD, United Kingdom, April 14, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced that …
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer
GlobeNewswire
·
April 14, 2025
Mr. Salus Brings More than 30 Years of Broad-Based Legal and Management Expertise Highlighted by Extensive Experience within Life Sciences Industry Significantly Elevates Lifecore’s Capabilities Across Corporate Governance, Transactional Activities, and …
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
GlobeNewswire
·
April 14, 2025
LEIDEN, Netherlands …
Soleno Therapeutics Announces VYKAT(TM) XR Launch
GlobeNewswire
·
April 14, 2025
REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of …